Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VE303
- Development stage
- Phase 3
- Lead developer
- Vedanta Biosciences
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**VE303** is an investigational, orally administered live biotherapeutic product from Vedanta Biosciences for prevention of recurrent *Clostridioides difficile* infection. It is a standardized, defined consortium of eight purified clonal strains of live commensal bacteria, manufactured from clonal cell banks rather than donor stool. The consortium is designed to restore colonization resistance after antibiotic-associated microbiome disruption by competing with *C. difficile* for growth substrates and producing secondary bile acids and short-chain fatty acids that suppress pathogen expansion and support gut-barrier and anti-inflammatory functions. VE303 is being evaluated in the pivotal Phase 3 RESTORATiVE303 trial. ([vedantabio.com](https://www.vedantabio.com/pipeline-programs/ve303/))
- Other names
- clostridia, cluster iv, strain relative flavonifractor plautii, liveVE303 consortiumVE-303 consortiumVE 303 consortium8-strain bacterial consortium
Beyond the preview
Go deeper on VE303.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VE303.